Dr. Arun Menawat reports
GROWING BODY OF CLINICAL EVIDENCE POINTS TO THE POTENTIAL OF PROFOUND MEDICAL'S TULSA PROCEDURE BECOMING A MAINSTREAM TREATMENT MODALITY ACROSS THE ENTIRE PROSTATE DISEASE SPECTRUM
A total of 25 paper, poster and podium presentations highlighting the transurethral ultrasound ablation (Tulsa) procedure's ability to effectively, safely and efficiently treat an unrivalled variety of prostate cancer and/or benign prostatic hyperplasia patients have been made at major medical meetings already in 2024.
"The Tact five-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of Tulsa from U.S. commercial centres, such as Mayo Clinic in Florida, Busch Center in Georgia and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, Alta Klinik in Germany and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of Tulsa as a mainstream treatment for prostate disease," said Dr. Arun Menawat, Profound's chief executive officer and chairman.
Of the 25 Tulsa presentations delivered year to date, five were given at the European Congress of Radiology (Feb. 29 to March 3, Vienna, Austria), one at the annual meeting of the southeastern section of the American Urological Association (March 20 to March 23, Austin, Tex.), three at the Society of Interventional Radiology (SIR) annual scientific meeting (March 23 to March 28, Salt Lake City, Utah), five at the Annual European Association of Urology congress (April 5 to April 8, Paris, France), one at the Society of Abdominal Radiology annual meeting (April 14 to April 19, Hollywood, Fla.), one at the Japanese Urological Association annual meeting (April 25 to April 27, Kobe, Japan), one at the American Roentgen Ray Society annual meeting (May 5 to May 9, Boston, Mass.) and eight at the AUA's annual meeting in San Antonio, Tex., which just concluded today.
"The various presentations made at AUA and other major medical conferences have highlighted Tulsa's clinical use across the entire prostate disease spectrum, ranging from low-, intermediate- or high-risk prostate cancer to hybrid patients suffering from both prostate cancer and BPH to men with BPH only, and also to patients requiring salvage therapy for radio-recurrent localized prostate cancer," added Dr. Menawat. "Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the Tact [Food and Drug Administration] regulatory study. We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of Tulsa among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses."
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing Tulsa-Pro, a technology that combines real-time MRI, robotically driven transurethral ultrasound and closed-loop temperature feedback control. Tulsa-Pro is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient's natural functional abilities. Tulsa-Pro has the potential to be a flexible technology in customizable prostate ablation, including intermediate-stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume-benign prostatic hyperplasia. Tulsa-Pro is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.
Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a humanitarian device exemption for the treatment of osteoid osteoma. The company is in the early stages of exploring additional potential treatment markets for Sonalleve, where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.